Two major milestones recently galvanized the Focused Ultrasound Foundation’s pediatrics program:

1. **New Center of Excellence**
   Foundation named Children’s National Hospital in Washington, DC, its first pediatric Center of Excellence. This designation will foster and encourage research into the pediatric oncological applications of focused ultrasound.

2. **First US regulatory approval**
   US Food and Drug Administration, FDA, approved the Profound Medical Sonalleve device for treating osteoid osteoma. This is the first US regulatory approval for an indication that occurs primarily in children and young adults.

An early-stage, noninvasive therapeutic technology, focused ultrasound has the potential to improve the quality of life and decrease the cost of care for pediatric patients with a multitude of different diseases and conditions. This technology could provide an alternative to invasive surgery, replace or complement radiation therapy and enhance drug delivery in pediatric patients with brain tumors, sarcomas, desmoid tumors, bone metastases and osteoid osteomas.
Help us revolutionize treatment for children by funding studies that will develop strategies for a wide variety of diseases.

Focused ultrasound precisely focuses beams of ultrasound energy on targets deep within the brain and body without damaging surrounding normal tissue. Where the beams converge, the ultrasound can produce a variety of therapeutic effects on tissue, enabling the incisionless treatment of conditions affecting the pediatric population. The advantages of focused ultrasound over other treatment modalities are especially appealing to the field of pediatrics. The advantages are:

- **No incisions** | No infection risk, less pain
- **Image guided** | Precision targeting
- **No ionizing radiation** | Fewer side effects
- **Enhanced drug delivery** | Reduced toxicity

Pediatrics fireside chat

The Foundation’s Director of Clinical Relationships, Suzanne LeBlang, MD, shared valuable insights on the latest research and developments in focused ultrasound for pediatric indications.

Osteoid osteoma is the first US regulatory approval that will directly impact pediatric patients. We believe that more approvals for pediatrics are forthcoming. Watch on YouTube.

Pediatric research areas

- **Neurological**
  - Astrocytoma
  - Epilepsy
  - Hydrocephalus
  - Papilloma
  - Brain glioma
- **Cardiovascular**
  - Coarctation of the aorta
  - Hypoplastic left heart syndrome
  - Septal perforation
- **Miscellaneous**
  - Multiple tumors
- **Urological**
  - Ureterocele
- **Musculoskeletal**
  - Bone metastases
  - Desmoid tumors
  - Osteoid osteoma
  - Soft tissue injury
  - Soft tissue tumors, benign
  - Sacral chordoma

Your gift’s impact

We have launched a five-year, $60 million campaign of which at least $3 million will be dedicated to pediatric research.

Hear from osteoid osteoma patient Della about her successful focused ultrasound clinical trial experience. Watch on YouTube.

Foundation focus pediatric brain tumors

The Foundation convened clinical experts, industry leaders, and FDA representatives to outline current practices in the treatment of benign pediatric brain tumors and determine a roadmap for advancing focused ultrasound as a treatment option.
About Focused Ultrasound Foundation

The Focused Ultrasound Foundation is an entrepreneurial, high-performance, medical research, education and patient advocacy organization headquartered in Charlottesville, VA. On the leading edge of venture philanthropy and social entrepreneurship, the Foundation has demonstrated success in accelerating the development and adoption of focused ultrasound, an early-stage, noninvasive therapeutic technology that could transform the treatment of many medical disorders. The Foundation is a 501(c)(3) tax-exempt organization that uses donor funding to bridge the gap between laboratory research and widespread patient treatment.

For more information

Jessica Lukens
Development Officer
434.326.0924
Email >

fusfoundation.org